Free Trial
NYSE:MTNB

Matinas Biopharma 8/14/2024 Earnings Report

Matinas Biopharma logo
$0.84 -0.03 (-3.31%)
As of 09:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Matinas Biopharma EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.02
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Matinas Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Matinas Biopharma Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Matinas Biopharma Earnings Headlines

How I make 💰 trading from 135 countries
I’ve traveled to 135 countries… In a new time zone almost every week… (Often 8… 12… 16 hours AHEAD of the United States) And yet I’ve made $7.9 million career profits… trading in the US markets?
Matinas BioPharma appoints Murphy, Neugeboren to board of directors
See More Matinas Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Matinas Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Matinas Biopharma and other key companies, straight to your email.

About Matinas Biopharma

Matinas Biopharma (NYSE:MTNB) is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

View Matinas Biopharma Profile

More Earnings Resources from MarketBeat